Recruiting

REFINeAI-Supported Diagnostic Accuracy Improvement in Nephrology

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

AI suggestion

Other
Who is being recruted

Disease

+ Pathologic Processes

+ Pathological Conditions, Signs and Symptoms

Over 18 Years
+8 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Diagnostic Study

Interventional
Study Start: November 2025
See protocol details

Summary

Principal SponsorUniversity Hospital, Lille
Study ContactRaphaël BENTEGEAC, MD, MPH
Last updated: January 21, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: November 20, 2025

Actual date on which the first participant was enrolled.

This study is all about improving the diagnosis of kidney-related diseases, also known as nephrology cases. It explores whether providing doctors with real-time diagnostic suggestions from a high-performing AI model, specifically GPT-5, can enhance their diagnostic accuracy, confidence, and efficiency. The study is important because it could potentially revolutionize the way nephrology diagnoses are made, leading to improved patient care and addressing current challenges in this field. The study involves medical students, residents, fellows, and practicing physicians. Participants are divided into two groups: one group receives AI support, while the other group does not. Participants in both groups are presented with 10 nephrology cases to solve, and they can complete these cases over multiple sessions. In the AI-supported group, participants first provide their initial diagnoses and confidence ratings without AI assistance. Then, they are shown GPT-5's diagnostic suggestions, after which they can revise their diagnoses once. In the control group, participants view each case and provide up to three diagnoses followed by a confidence rating. The study measures initial and final diagnoses, confidence ratings, completion times, and participant demographic variables. The primary outcome is the diagnostic accuracy with and without AI support.

Official TitleReasoning Enhancement With Feedback From a Generative AI in Nephrology (REFINe): A Randomized Evaluation of Generative AI Support in Nephrology Diagnosis 
Principal SponsorUniversity Hospital, Lille
Study ContactRaphaël BENTEGEAC, MD, MPH
Last updated: January 21, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

100 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Diagnostic Study

Diagnostic studies focus on improving how we detect or confirm a disease. They test new tools or techniques that could provide faster or more accurate diagnoses.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

DiseasePathologic ProcessesPathological Conditions, Signs and Symptoms

Criteria

5 inclusion criteria required to participate
Adults aged 18 years or older.

Able to read and answer clinical vignettes in English or French.

Access to a computer or smartphone with an internet connection.

Provides informed consent online.

Show More Criteria

3 exclusion criteria prevent from participating
Individuals under 18 years of age.

Inability to complete online study procedures.

Prior involvement in the design, development, or evaluation of the AI system used in this study.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Participants in this arm will complete the same clinical case vignettes as the control group. For each case, they will receive a suggested diagnosis generated by a large language model (GPT-5, high-reasoning configuration), which was selected after internal benchmarking. Participants can review the AI suggestion before entering their own final diagnostic answer. No additional information, prompts, or coaching is provided. The intervention consists solely of displaying the AI-generated diagnostic suggestion during the case-solving task.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

Lille University Hospital (online study)

Lille, FranceSee the location
Recruiting
One Study Center